An observational study in Hereditary Spherocytosis and Hemolytic Anemia, sponsored by Assiut University. Not yet recruiting. Open to participants aged 1 Month to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Assiut University · Observational
This cross-sectional study aims to evaluate the diagnostic performance of selected automated complete blood count-derived erythrocytic and reticulocytic parameters in children with hereditary spherocytosis.
Hereditary spherocytosis is an inherited red blood cell membrane disorder. Modern automated hematology analyzers provide additional erythrocytic and reticulocytic parameters that may aid in its recognition.
This observational study will include children with confirmed or clinically suspected hereditary spherocytosis and a comparison group without hereditary spherocytosis. Complete blood count and reticulocyte parameters including mean reticulocyte volume (MRV), immature reticulocyte fraction (IRF), Ret/IRF ratio, and MicroR will be evaluated.
56 studies on the registry are indexed under Anemia, Hemolytic; 16 are open to participants now.
This study's planned enrollment of 41 is below the median of 56 across 16 observational studies indexed under Anemia, Hemolytic.
Browse Anemia, Hemolytic studies →Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Children aged 1 month to 18 years evaluated for hereditary spherocytosis or included as comparison participants at Assiut University Children's Hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Children with confirmed hereditary spherocytosis.
Age-appropriate children without evidence of hereditary spherocytosis.
Diagnostic performance of mean reticulocyte volume (MRV)
Sensitivity, specificity, and area under the receiver operating characteristic (ROC) curve of mean reticulocyte volume (MRV) for identifying hereditary spherocytosis.
Time frame: Baseline
Diagnostic performance of Ret/IRF ratio
Sensitivity, specificity, and area under the ROC curve of the reticulocyte/IRF ratio for identifying hereditary spherocytosis.
Time frame: Baseline
Diagnostic performance of immature reticulocyte fraction (IRF)
Sensitivity, specificity, and area under the ROC curve of immature reticulocyte fraction for identifying hereditary spherocytosis.
Time frame: Baseline
Diagnostic performance of MicroR
Sensitivity, specificity, and area under the ROC curve of percentage of microcytic red cells (MicroR) for identifying hereditary spherocytosis.
Time frame: Baseline
Mean hemoglobin level
Mean hemoglobin concentration in g/dL compared between hereditary spherocytosis and non-hereditary spherocytosis groups.
Time frame: Baseline
Mean MCHC
Mean corpuscular hemoglobin concentration compared between groups.
Time frame: Baseline
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.